September 29, 2017

CAAR – Lancet Article Abstract – September 29, 2017

Filed under: Reports and Articles — Tags: — admin @ 4:47 pm

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial,” by Bente L. Langdahl, Cesar Libanati, Daria B. Crittenden, Michael A. Bolognese, Jacques P. Brown, Nadia S. Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S. Finkelstein, Harry K. Genant, Stefan Goemaere, Lars Hyldstrup, Esteban Jodar-Gimeno, Tony M. Keaveny, David Kendler, Peter Lakatos, Judy Maddox, Jorge Malouf, Fabio E. Massari, Jose Fernando Molina, Maria Rosa Ulla, and Andreas Grauer (Vol. 390, No. 10102, September 30, 2017, p. 1585-1594).

No Comments

No comments yet.

RSS feed for comments on this post.

Sorry, the comment form is closed at this time.

Powered by WordPress